Multi-Omics Study Reveals Immune Cell Genes Linked to Parkinson’s Disease, Highlights Drug Repurposing Candidates

Immune Cell Genetics Reveal Parkinson’s Disease Mechanisms

Researchers have identified 28 immune cell-specific genes that significantly influence Parkinson’s disease risk through a sophisticated multi-omics approach, according to a recent study published in npj Parkinson’s Disease. The investigation, which combined genetic analysis with drug database screening, reportedly reveals novel mechanisms by which peripheral immune cells contribute to PD pathogenesis and identifies several promising drug repurposing candidates.

Immune Cell Genetics Reveal Parkinson’s Disease Mechanisms
Key Genetic Findings Across Immune Cell Types
Therapeutic Implications and Drug Repurposing Potential
Validation and Clinical Relevance
Research Implications and Future Directions

Sources indicate the study employed Mendelian randomization and Bayesian colocalization analyses to establish causal relationships between gene expression in specific immune cell types and Parkinson’s disease development. The research team analyzed data from 14 distinct immune cell populations, with sample sizes ranging from 643 to 982 individuals, creating what analysts describe as one of the most comprehensive assessments of immune cell-specific genetic influences on PD to date.

Key Genetic Findings Across Immune Cell Types

The report states that researchers initially detected 26,597 expression quantitative trait loci (eQTL) genes across multiple immune subsets, which were refined to 8,733 distinct genes after applying stringent statistical filters. According to the analysis, CD4 naïve/central memory T cells and natural killer cells contained the largest shares of these genetic instruments.

Notably, the study identified FDFT1 as showing consistent associations across multiple cell types, including CD4 and CD8 T cell subsets as well as memory B cells, suggesting what researchers describe as a broad regulatory role in PD susceptibility. Other significant genes included HLA-DQA1, HLA-DQA2, and CTSB, which were significantly linked to PD in CD8 T cells, natural killer cells, and monocytes, indicating immune-related and lysosomal pathways in disease development.

Analysts suggest that DGKQ displayed the strongest association specifically in natural killer cells, pointing to a novel and highly cell-specific risk mechanism. The report states that Bayesian colocalization analysis further refined these findings, identifying 24 immune-cell-specific genes with evidence of shared causal variants for both gene expression and PD risk.

Therapeutic Implications and Drug Repurposing Potential

Perhaps most significantly, drug enrichment analysis revealed several existing compounds with potential for therapeutic repurposing in Parkinson’s disease. According to reports, high-ranking candidates included leupeptin, DNQX, and β-solamarine, all showing strong enrichment for targeting CTSB and ARSA genes.

The study indicates that FDFT1 was targeted by drugs including mitoxantrone, tetrandrine, and pravastatin—the latter already being an approved cholesterol-lowering agent, making it what researchers describe as a viable repositioning candidate. CTSB, a lysosomal protease linked to PD pathology, was reportedly targeted by multiple compounds with diverse indications such as amodiaquine (antimalarial), trifluridine (antiviral), and alprazolam (anxiolytic).

Researchers conducted molecular docking simulations to evaluate binding interactions, with sources indicating that felodipine and amodiaquine exhibited the most favorable binding energies for CTSB among blood-brain-barrier-permeant compounds. Several non-BBB-permeant compounds also demonstrated strong predicted binding, suggesting potential utility in peripheral modulation strategies.

Validation and Clinical Relevance

The report states that replication analysis using the DICE project confirmed significant associations for three of four tested genes, supporting the robustness of the primary findings. Additionally, researchers analyzed an independent peripheral blood single-cell RNA sequencing dataset profiling six individuals, including Parkinson’s patients and healthy controls.

According to the analysis, several genetically prioritized genes showed robust expression in distinct immune cell populations, with differential expression analysis revealing cell-type-specific transcriptional alterations in PD patients. Statistical testing reportedly identified significant expression changes for HLA-DQA1, DDRGK1, and ZNF391 in CD8 T cells, and for KRTCAP3 in CD4 T cells, with effect directions consistent with the primary genetic findings.

To assess potential side effects and broader relevance, researchers performed phenome-wide association studies, which indicated that most prioritized genes showed no significant associations at the genome-wide level, suggesting what analysts describe as a low risk of widespread off-target effects. However, some genes were linked to other conditions, providing important safety context for future therapeutic development.

Research Implications and Future Directions

The comprehensive nature of this multi-omics investigation provides what sources characterize as unprecedented insights into the immune-mediated genetic architecture of Parkinson’s disease. By integrating genetic causality assessment with drug database screening and molecular docking simulations, the study establishes a framework for identifying and prioritizing therapeutic candidates.

Researchers suggest that the distinction between blood-brain-barrier-permeant and non-permeant compounds provides important pharmacokinetic context for prioritizing drugs in future central nervous system-targeted versus peripheral immune modulation strategies. The identification of both novel genetic mechanisms and repurposing candidates represents what analysts describe as a significant advance toward developing immune-targeted therapies for Parkinson’s disease.

References & Further Reading

This article draws from multiple authoritative sources. For more information, please consult:

This article aggregates information from publicly available sources. All trademarks and copyrights belong to their respective owners.

Note: Featured image is for illustrative purposes only and does not represent any specific product, service, or entity mentioned in this article.

Scientists have developed the most complete map yet of genetic mutations that cause treatment resistance in chronic myeloid leukemia. The breakthrough study used advanced gene editing to test nearly all possible mutations against five generations of targeted therapies.

Breakthrough in Understanding Cancer Drug Resistance

Researchers have created the most comprehensive map to date of genetic mutations that cause resistance to chronic myeloid leukemia (CML) treatments, according to a recent study published in Nature Biomedical Engineering. The research team used prime editing, an advanced gene-editing technology, to systematically test how nearly all possible mutations in the ABL1 gene affect response to five different tyrosine kinase inhibitors (TKIs).